MILWAUKEE, Oct. 7, 2013 (GLOBE NEWSWIRE) -- We are investigating possible securities fraud claims against Atossa Genetics Inc. resulting from inaccurate statements Atossa made regarding its financial statements and prospects.
Click here to learn more about the investigation: http://www.ademilaw.com/case/Atossa or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Our investigation focuses on the extent to which Atossa issued false and misleading statements regarding its financial statement, past and future business performance and prospects. Specifically, Atossa failed to disclose that its ForeCYTE Breast Health Test and its Mammary Aspiration Specimen Cytology Test (MASCT) device did not comply with the U.S. Food and Drug Administration (FDA) rules and regulations. On October 4, 2013, Atossa announced that it was removing the ForeCYTE Breast Health Test and the MASCT device from the market to address concerns raised by the FDA in a warning letter received by Atossa in February 2013. The FDA raised concerns about (1) the current instructions for use (IFU); (2) certain promotional claims used to market these devices; and (3) the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid (NAF) specimen collection process identified in the current IFU.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Ademi & O'Reilly, LLP Guri Ademi 3620 East Layton Ave. Cudahy, WI 53110 Toll Free: (866) 264-3995 Fax: (414) 482-8001 www.ademilaw.comSource:Ademi & O'Reilly, LLP